Zhejiang Provincial People's Hospital
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, China34 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Recruiting | Phase 1 / Phase 2 | 2026-10-09 | NCT06139575 | |
| Anesthesia and Perioperative Neurocognitive Disorders in the Elderly Patients Undergoing Hip Fracture Surgery Platform Trial (ANDES Platform Trial) | Cognition Disorders, Cognitive Decline, Cognitive Dysfunction, Femoral Fractures, Hip Injuries, Leg Injuries, bone fracture, brain disorder, central nervous system disorder, cognitive disorder, dementia, hip fracture, injury, nervous system disorder, psychiatric disorder | Recruiting | Not applicable | 2026-09-25 | NCT06452147 | |
| Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) for Injection to Treat Moderate to Severe Glabellar Lines | Moderate to Severe Glabellar Lines | Recruiting | Phase 3 | 2026-09-23 | NCT06937944 | |
| Study on the Efficacy and Safety of Different Doses of PEG-rhG-CSF for Primary Prevention of Febrile Neutropenia | cancer, neoplasm | Enrolling by invitation | Not stated | 2026-09-18 | NCT07829276 | |
| A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Recruiting | Phase 2 / Phase 3 | 2026-09-17 | NCT06361888 | |
| Renal Oxygenation-Guided AKI Reduction Trial | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Urogenital Diseases, acute kidney injury, kidney disorder, kidney failure, urinary system disorder | Not yet recruiting | Not applicable | 2026-09-14 | NCT07816640 | |
| Phase 3 Study to Evaluate the Efficacy and Safety of Human Growth Hormone Injection (Sinotropin AQ) for the Treatment of Children With Idiopathic Short Stature | Idiopathic Short Stature (ISS) | Not yet recruiting | Phase 3 | 2026-09-11 | NCT07815626 | |
| A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD | eye disorder, macular degeneration, retinal degeneration, retinal disorder | Recruiting | Not stated | 2026-09-01 | NCT06346600 | |
| A Study of ATG-022 Compared With Investigator's Choice of Treatment in Claudin 18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | Not yet recruiting | Phase 3 | 2026-08-31 | NCT07795346 | |
| Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD) | Neovascular Age-related Macular Degeneration | Recruiting | Phase 1 / Phase 2 | 2026-08-28 | NCT05986864 | |
| Efficacy and Safety of Roflumilast Foam 0.3% in Trial Participants With Seborrheic Dermatitis | Skin Diseases, Eczematous, Skin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, dermatitis, sebaceous gland disorder, seborrheic dermatitis, skin disorder | Not yet recruiting | Phase 3 | 2026-08-21 | NCT07683806 | |
| A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE) | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-08-11 | NCT06680921 | |
| Efficacy and Safety of Scheduled Versus As-Needed Firsekibart Administration for the Prevention of Gout Recurrence: A Multicenter, Open-Label, Randomized Controlled Trial | Gout Flares | Not yet recruiting | Not applicable | 2026-06-01 | NCT07616531 | |
| China Diabetes Type 1 Study (CD1S) by China Alliance for Type 1 Diabetes | Nutritional and Metabolic Diseases, autoimmune disease, diabetes mellitus, endocrine system disorder, glucose metabolism disease, immune system disorder, metabolic disease, type 1 diabetes mellitus | Recruiting | Not stated | 2026-04-28 | NCT05498974 | |
| Neoadjuvant Treatment of Locally Advanced HNSCC With Pertuzumab Combined With Lenvatinib. | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, neoplasm, squamous cell carcinoma | Enrolling by invitation | Phase 2 | 2026-04-24 | NCT07550972 | |
| Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Diabetic Macular Edema | Diabetic Macular Edema (DME) | Recruiting | Phase 3 | 2026-04-07 | NCT07515079 | |
| The Chinese Familial Alzheimer's Network | Alzheimer disease, Familial Alzheimer Disease (FAD), brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Recruiting | Not stated | 2026-03-23 | NCT03657732 | |
| China Cognition and Aging Study | Alzheimer Disease, Late Onset, Alzheimer disease, Arterial Occlusive Diseases, Cognition Disorders, Cognitive Dysfunction, Familial Alzheimer Disease (FAD), Leukoencephalopathies, arteriosclerosis disorder, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, cognitive disorder, dementia, intracranial arterial disease, intracranial arteriosclerosis, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy, vascular dementia, vascular disorder | Recruiting | Not stated | 2026-03-23 | NCT03653156 | |
| A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation. | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Recruiting | Phase 2 | 2026-03-13 | NCT06008288 | |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase Ⅱ Clinical Study to Evaluate the Efficacy and Safety of CMS-D001 in Adult Patients With Moderate to Severe Atopic Dermatitis | Moderate to Severe Atopic Dermatitis | Not yet recruiting | Phase 2 | 2026-03-11 | NCT07465120 | |
| A Clinical Study Evaluating the Efficacy and Safety of CMS-D001 Tablets in the Treatment of Adult Patients With Moderate to Severe Plaque-type Psoriasis | Moderate to Severe Plaque Psoriasis | Not yet recruiting | Phase 2 / Phase 3 | 2026-02-25 | NCT07432854 | |
| Additive Anti-inflammatory Action for Aortopathy & Arteriopathy | Acute Aortic Syndrome, aortic disorder, cardiovascular disorder, vascular disorder | Recruiting | Not stated | 2026-02-09 | NCT04398992 | |
| LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-01-26 | NCT07312422 | |
| A Study of Telitacicept for IgA Nephropathy (TELIGAN) | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, IgA glomerulonephritis, Male Urogenital Diseases, Urogenital Diseases, autoimmune disease, glomerulonephritis, immune system disorder, kidney disorder, nephritis, urinary system disorder | Active, not recruiting | Phase 3 | 2025-12-16 | NCT05799287 | |
| Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction | cardiovascular disorder, coronary artery disorder, heart disorder, myocardial ischemia, vascular disorder | Recruiting | Phase 4 | 2025-11-25 | NCT07110415 |